LENZ Therapeutics Inc Dossier
Qualitative Analysis
Business overview
LENZ Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmic therapies to improve vision. The company's primary focus is VIZZu0000 (aceclidine ophthalmic solution) 1.44%, which received FDA approval in July 2025 as the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. VIZZu0000 is designed to restore clear near vision for up to 10 hours by utilizing a predominantly pupil-selective miotic mechanism that avoids overstimulating the ciliary muscles. LENZ is commercializing VIZZu0000 in the United States while establishing international licensing and distribution partnerships to expand global access.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercializing VIZZ (aceclidine ophthalmic solution) 1.44% in the United States, supported by a nationwide sales force and a direct-to-consumer (DTC) marketing campaign featuring Sarah Jessica Parker.
Expected impact: Establish VIZZ as a leading once-daily pharmacological treatment for presbyopia, driving prescription growth and long-term product revenue.
Establishing licensing, distribution, and commercialization partnerships internationally to maximize the global value of VIZZ.
Expected impact: Expands the global footprint of VIZZ across Europe, the UK, Greater China, South Korea, Southeast Asia, Canada, and the Middle East, generating milestone payments and royalty streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Everest Medicines acquired the rights to develop, manufacture, and commercialize VIZZ (LNZ100) for presbyopia in Greater China (Chinese mainland, Hong Kong, Macao, and Taiwan).
Terms: LENZ is eligible to receive up to $85 million in remaining regulatory and sales milestones, plus tiered mid-single-digit to low-double-digit royalties on net sales in Greater China.
Lunatus holds exclusive rights to register and commercialize VIZZ for the treatment of presbyopia in the Middle East region (including UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq).
Terms: LENZ received an upfront payment of approximately $0.2 million in Q1 2026 and is eligible for future regulatory and commercial milestones, plus a significant share of regional revenue through a pre-determined minimum product supply price.